Asbestos Home Test Kit
Asbestos is a health hazard in many homes, offices and schools. - Asbestos exposure can cause lung cancer. - Order an easy to use Home Test right now!
View ArticleClik here to view.
Hycamtin Achieves Promising Results in Patients With Non-Small Cell Lung Cancer
DENVER, May 19 /PRNewswire/ - According to a study presented today at the 33rd annual meeting of the American Society of Clinical Oncology , Hycamtin (topotecan hydrochloride for injection, SmithKline...
View ArticleClik here to view.
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy...
M2 PRESSWIRE-5 May 2009-Research and Markets: Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report1994-2009 M2 COMMUNICATIONS LTD RDATE:05052009 Dublin -...
View ArticleClik here to view.
ImmunoGen Begins Enrollment in a Third Phase I/II Human Clinical Study with...
Clinical Trial Designed to Study Safety of Compound in a More Dose-Intensive Regimen; Clinical Development Program Continues on Track CAMBRIDGE, Mass., May 8 /PRNewswire/ - ImmunoGen, Inc. today...
View ArticleClik here to view.
ImmunoGen Reports Promising Results from Phase I/II Human Clinical Study with...
-Data Reported at the 2001 Annual Meeting of American Society of Clinical Oncology- CAMBRIDGE, Mass., May 14 /PRNewswire/ - ImmunoGen, Inc. today announced safety and pharmacokinetic data from 37...
View ArticleClik here to view.
ImmunoGen Reports Results from Phase I/II Human Clinical Study with Product...
-Data Reported at the 2001 Annual Meeting of American Society of Clinical Oncology- CAMBRIDGE, Mass., May 13 /PRNewswire/ - ImmunoGen, Inc. today announced safety and pharmacokinetic data from 37...
View ArticleClik here to view.
Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds...
WESTMINSTER, Colo., June 14 /PRNewswire-FirstCall/ - Allos Therapeutics, Inc. today announced the publication of new findings from its Phase 3 REACH study of EFAPROXYN plus whole brain radiation...
View ArticleClik here to view.
N-terminal deletion augments BAX activity in non-small cell lung cancers.
2003 JUN 23 - - N-terminal deletion augments BAX activity in non-small cell lung cancers. According to recent research from Japan, "therapeutic modalities that overcome the antiapoptotic function of...
View ArticleClik here to view.
HER-2, EGFR, and COX-2 are overexpressed in some non-small cell lung cancers.
2004 MAR 30 - - HER-2, EGFR, and COX-2 are overexpressed in some non-small cell lung cancers. According to recent research published in the journal Acta Oncologica, "the incidence of lung cancer is...
View ArticleClik here to view.
COX-2 and tumor angiogenesis correlate in non-small cell lung cancers.
2003 DEC 16 - - COX-2 and tumor angiogenesis correlate in non-small cell lung cancers. "The role of cyclooxygenase -2 expression and angiogenesis of lung cancer is yet to be delineated. Eighty four...
View ArticleClik here to view.
Metastatic non-small-cell lung cancers overexpress the SKP2 gene.
2004 AUG 24 - - Metastatic non-small-cell lung cancers overexpress the SKP2 gene. According to a study from Japan, "SKP2, an F-box protein constituting the substrate recognition subunit of the SCFSKP2...
View ArticleLung Cancer Ribbon
Lung Cancer Support Ribbon Lapel Pins. - Made in U.S.A. - Help Increase Lung Tumor Awareness and Early Detection.
View ArticleClik here to view.
One of World's Deadliest Cancers Eliminated from Lungs of Mice by New Drug,...
Oct. 29, 2009One of the most dangerous of cancersnon-small cell lung (NSCL) cancerhas been totally eliminated from laboratory mice at UT Southwestern Medical Center by the use of an investigative drug...
View ArticleClik here to view.
November Is Lung Cancer Month: Know The Latest Information About This...
Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year.(1) It is also estimated that lung cancer will cause 159,000 deaths in the...
View ArticleClik here to view.
Celera to use Medical Therapies' midkine patent portfolio for development of...
Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have...
View ArticleClik here to view.
Novel therapy may eradicate lung cancer
Washington, Oct 30 : Scientists from UT Southwestern Medical Center have suggested a novel therapeutic strategy that would completely eradicate lung cancer.
View ArticleClik here to view.
Celera Licenses Protein IP for Lung Cancer Dx
NEW YORK (GenomeWeb News)Celera said today that it has licensed the rights to use Medical Therapies Limited's patent portfolio for the protein midkine in its lung cancer diagnostics programs.
View ArticleClik here to view.
Intervals between lung cancer diagnosis and treatment displays a health care...
( International Association for the Study of Lung Cancer ) Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion,...
View ArticleClik here to view.
Drug-radiation Combo Eradicates Lung Cancer In Mice
Researchers have eliminated non-small cell lung cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.
View ArticleClik here to view.
Drug-Radiation Combo Used To Eradicate Lung Cancer
Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.In a study...
View Article
